3OCT

Cholera killed 7,870 in 2025, WHO says

2 min read

13:42UTC

WHO's annual report counts 7,870 cholera deaths reported by 47 countries in 2025, the most since 1999, even as vaccine output rose to 80 million doses a year.

← Back to River boat carries Ebola 1,000 km downriver Jump to analysis ↓

ScienceDeveloping

Key takeaway

Cholera deaths hit a 26-year high in 2025 despite far more vaccine.

The World Health Organization (WHO) recorded 451,499 Cholera cases and 7,870 deaths reported by 47 countries in 2025, in its annual report released on 29 September⁠¹. No year since 1999 has produced more Cholera deaths reported to WHO. Cholera is a waterborne diarrhoeal disease that kills through dehydration, and most patients survive if they get oral rehydration salts in time.

Oral Cholera vaccine output rose from about 30 million to 80 million doses a year, so deaths climbed even as supply grew. Vaccines buy protection in an outbreak zone; deaths track how quickly the sick reach treatment. WHO's regional record for June showed the same split, with Sudan losing four times as many patients as Afghanistan on a far smaller case count.

Deep Analysis

In plain English

People catch Cholera, a bacterial infection, from dirty water or food. It causes severe diarrhoea and can kill within hours through dehydration, but it is easy to treat with clean fluids if people reach help in time. In 2025, more people died of Cholera than in any year reported to WHO since 1999. Most deaths were in countries at war or in crisis, such as Sudan and Yemen. The world now makes far more Cholera vaccine than a few years ago. But most doses are used after outbreaks start, and without clean water and nearby clinics, people keep dying.

Deep Analysis

Root Causes

Cholera spreads through water and food contaminated with sewage, so it tracks war, displacement and flooding. Sudan's civil war, Yemen's long conflict and eastern DR Congo's fighting all damage water systems and push people into crowded camps.

Deaths rise when people cannot reach treatment. Cholera kills through dehydration, which oral rehydration salts can usually reverse within hours, so a high case-fatality ratio signals distance from care rather than a deadlier strain.

In the African Region, cases rose 34% but deaths 58%, so each case became more likely to kill, the pattern expected when outbreaks reach areas with weak clinics.

What could happen next?

Consequence
WHO and Gavi are likely to push more of the larger vaccine supply into preventive campaigns before outbreak seasons.
Risk
With Sudan, Yemen and DR Congo still in conflict, 2026 deaths may stay at or near 2025's level.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: Yemen's Cholera epidemic from 2016 became one of the largest in modern records as war destroyed water and sewage systems. Its first oral vaccine campaign came only in May 2018, long after the peak, the same reactive pattern WHO's 2025 data show.

Counter-parallel: In early 2018 Zambia ran a city-wide oral vaccine campaign in Lusaka alongside water chlorination and a ban on street food, and declared the outbreak over within months. Vaccine combined with water work stopped deaths where water systems still functioned.

Vaccine production roughly doubled between 2022 and 2025, easing a shortage that in 2022 forced the ICG to cut the standard dose from two to one. By 2025 cheap vaccine was available in volume.

The structural cost lies in water and sanitation, which vaccines cannot replace and which needs long-term capital spending that emergency budgets do not cover.

Consensus view: WHO's report places the problem in a few crisis states: Angola, Bangladesh, DR Congo, Nigeria, South Sudan, Sudan and Yemen carried about 90% of cases and deaths, and 12 countries exceeded the 1% case-fatality threshold that marks failing treatment. On this view, WHO's fix lies in access to care in conflict zones.

Counter-view: The vaccine figures point elsewhere. The International Coordinating Group approved 71 million doses for 2025, but only 20 million for preventive campaigns; the rest went to emergency response after outbreaks began. On that reading supply is no longer the limit, and the failure is that doses arrive after the deaths start.

Key tension: Whether doubled vaccine output can shift from emergency use to prevention while water and sanitation in war zones keep failing.

Sources:World Health Organization

Mentions:WHO AFRO →World Health Organization →Cholera →Angola →Bangladesh →Sudan →Zambia →Afghanistan →Yemen →South Sudan →DR Congo →Nigeria →Lusaka →

First Reported In

Update #14 · River boat carries Ebola 1,000 km downriver

World Health Organization· 3 Oct 2026

Read original →

Different Perspectives

IGWG co-chair Tovar da Silva Nunes

The Brazilian co-chair closed the eighth pathogen-sharing session on 18 September without an agreed annex text, the second session in a row to end that way. He presented the outcome as continued commitment, with adoption due at the World Health Assembly in May 2027.

Fraport

The Frankfurt Airport operator has told staff to watch for fever, hessenschau reported, after six airport workers caught malaria. Germany does not require insecticide spraying of arriving aircraft cabins, and parasite genotyping to trace the source is due at the end of October.

European Centre for Disease Prevention and Control

ECDC reported the eight Frankfurt Airport malaria cases on 18 September and considers repeated arrivals of infected mosquitoes on aircraft likely. It has not ruled out local mosquitoes, and awaits genotyping due at the end of October.

Pan American Health Organization

PAHO counted 53,957 measles cases in the Americas by 19 September and is supporting Peru's response in Puno and Arequipa. It warns that October's Señor de los Milagros festivities and Pope Leo XIV's November visit could increase transmission.

Bangladesh Directorate General of Health Services

The DGHS recorded 1,030 measles-related deaths and 172,720 suspected cases by 14 September, after a campaign that reached 19.75 million children. Its disease-control director, Halimur Rashid, said further vaccination rounds were expected within two weeks.

Minapharm

The Egyptian drugmaker and its Berlin subsidiary ProBioGen were awarded up to US$16.5m by CEPI on 27 August to take a Bundibugyo vaccine into a Phase 1 trial in Africa. Final manufacture is planned for Cairo, making it CEPI's first Bundibugyo candidate with an African producer.